Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398865 · ClinicalTrials.gov registry record
Escitalopram Neuroimaging Supplement
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 23
- Enrollment target
NCT01398865: Completed study, sponsored by Massachusetts General Hospital.
NCT01398865 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398865 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to find out more about the brain's response to selective serotonin reuptake inhibitor (SSRIs) treatment in people with body dysmorphic disorder (BDD). The investigators will use positron emission tomography (PET) and Magnetic Resonance Imaging (MRI) scans to look at brain activity in people with BDD before and after treatment with an SSRI. The investigators hope that what is learned will allow prediction of whether someone will improve with SSRI treatment.
Interventions
- PROCEDURE PET scan and MRI scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01398865
The ClinicalTrials.gov registry entry for NCT01398865 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET scan and MRI scan is the first listed.
NCT01398865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01398865 about?
NCT01398865 is a clinical study titled "Escitalopram Neuroimaging Supplement". The purpose of this study is to find out more about the brain's response to selective serotonin reuptake inhibitor (SSRIs) treatment in people with body dysmorphic disorder (BDD). The investigators will use positron emission tomography (PET) and Magnetic Resonance Imaging (MRI) scans to look at brai...
What is the current status of trial NCT01398865?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2008-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01398865?
The interventions under investigation include: PET scan and MRI scan (PROCEDURE).
Who is sponsoring clinical trial NCT01398865?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.